Molecular Templates, Inc.

Equities

MTEM

US6085502085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.64 ^USD	+5.81%		+3.80%	-56.03%

Apr. 12	Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	CI
Apr. 09	Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	CI

Molecular Templates, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 13, 2021 at 04:30 pm EDT

Molecular Templates, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was USD 3.220 million compared to USD 4.141 million a year ago. Operating income was USD 26.329 million compared to USD 22.137 million a year ago. Net loss was USD 26.778 million compared to USD 22.018 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.48 a year ago.

Latest news about Molecular Templates, Inc.

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	Apr. 12	CI
Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	Apr. 09	CI
Molecular Templates, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Molecular Templates, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing: Investors Balance AI Hopes with Rate Concerns	Mar. 18	DJ
Molecular Templates, Inc. Provides Interim Update	Mar. 04	CI
Molecular Templates, Inc. Announces Board Changes	Jan. 17	CI
Molecular Templates, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q3 Revenue $6.8M	Nov. 13	MT
Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	Nov. 02	CI
Molecular Templates Names Chief Medical Officer	23-09-28	MT
Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023	23-09-28	CI
Molecular Templates' Board Approves 1-for-15 Reverse Stock Split	23-08-11	MT
Molecular Templates, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q2 Revenue $6.9M	23-08-10	MT
Molecular Templates Names Interim Chief Medical Officer, Other Executives	23-08-03	MT
Molecular Templates, Inc. Announces Executive Changes	23-08-02	CI
Molecular Templates, Inc. Announces Jason Kim Assumes the Role of Chief Financial Officer	23-08-02	CI
Molecular Templates Signs Deal for Up to $40 Million Private Placement	23-07-13	MT
Molecular Templates, Inc. announced that it expects to receive $40 million in funding	23-07-12	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell Microcap Value Index	23-06-23	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell 3000E Value Index	23-06-23	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell Microcap Growth Index	23-06-23	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell Microcap Index	23-06-23	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell 3000E Growth Index	23-06-23	CI

Chart Molecular Templates, Inc.

Duration

Period

More charts

Company Profile

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Companyâs proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Molecular Templates, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.64 USD

Average target price

18 USD

Spread / Average Target

+997.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECULAR TEMPLATES, INC.	-56.03%	8.81M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs